Skip to Content

What is the difference between Amjevita and Humira?

Medically reviewed by Last updated on Sep 16, 2019.

Official Answer


Amjevita (adalimumab-atto) is a biosimilar to Humira (adalimumab). Unlike Humira, Amjevita is not approved for the treatment of hidradenitis suppurativa or uveitis.

Amjevita (adalimumab-atto) is the first adalimumab (Humira) biosimilar approved by the FDA and, like Humira, is used in adults for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis; it is also approved for juvenile idiopathic arthritis (JIA) in children 4 years and older.

Amjevita is not approved to treat hidradenitis suppurativa, or uveitis, like Humira.

Amjevita is not approved as an interchangeable product at the pharmacy, meaning the pharmacist needs approval from the prescribing doctor to substitute Amjevita for Humira, if not specified on the prescription.

What Are Biosimilars? Top Facts You May Not Know

Like Humira, Amjevita is an anti-TNF-α monoclonal antibody that has the same amino acid sequence as adalimumab. 

Common side effects include infections and injection site reactions. Amjevita is available in a prefilled syringe or autoinjector and is given by a subcutaneous injection.

For more information, see Comparing Amjevita vs Humira

Related Medical Questions

Drug Information

Related Support Groups